Want to see IN:COHANCE full AI Analyst Report?
Top Page
Suven Pharmaceuticals Ltd.
(COHANCE)
Select Model
Select Model
Rating:56Neutral
Price Target:
₹472.00
▼(-47.03% Downside)
Action:Reiterated
Date:06/24/26
The score is held back primarily by the sharp FY2026 margin compression and weaker free-cash-flow conversion, along with a very high P/E valuation. Support comes from a low-leverage balance sheet and a generally constructive near-term technical setup (above key short-term moving averages), though the stock remains below its 200-day average.
Positive Factors
Revenue Growth
Sustained top-line acceleration indicates stronger demand for Suven's services and larger project throughput. Higher revenue supports better capacity utilization and creates a base for converting development projects to recurring commercial manufacturing, improving long-term revenue visibility.
Negative Factors
Margin Compression
Material, sustained margin deterioration weakens earnings quality and reduces internal funds for reinvestment. If structural (mix shift or pricing pressure), lower margins heighten sensitivity to cost inflation and limit ability to invest in capacity or absorb contract renegotiations over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained top-line acceleration indicates stronger demand for Suven's services and larger project throughput. Higher revenue supports better capacity utilization and creates a base for converting development projects to recurring commercial manufacturing, improving long-term revenue visibility.
Read all positive factors
Suven Pharmaceuticals Ltd. (COHANCE) vs. iShares MSCI India ETF (INDA)
Market Cap
₹168.34B
Dividend Yield1.68%
Average Volume (3M)342.93K
Price to Earnings (P/E)104.3
Beta (1Y)0.94
Revenue Growth41.24%
EPS Growth-70.51%
CountryIN
Employees1,193
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)4.22
Shares Outstanding382,597,320
10 Day Avg. Volume141,628
30 Day Avg. Volume342,932
Financial Highlights & Ratios
PEG Ratio-1.17
Price to Book (P/B)2.95
Price to Sales (P/S)5.08
P/FCF Ratio85.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹350.00Price Target Upside-60.72% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering1
EPS Forecast (FY)5.96
Revenue Forecast (FY)₹23.41B
Suven Pharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
Headquartered in Hyderabad, Cohance Lifesciences Limited operates as a pharmaceutical enterprise, with primary expertise in contract development and manufacturing (CDMO) services. Its business scope also includes the creation of active pharmaceuti...
How the Company Makes Money
Suven Pharmaceuticals primarily makes money by providing fee-for-service and contract manufacturing services to pharmaceutical and biotech customers. Its main revenue streams typically include: (1) Development services income—payments for process ...
Suven Pharmaceuticals Ltd. Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
84
Very Positive
Cash Flow
55
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 21.41B | 22.69B | 11.98B | 10.51B | 13.40B | 13.20B |
| Gross Profit | 11.44B | 9.11B | 8.22B | 6.80B | 7.52B | 7.46B |
| EBITDA | 3.27B | 4.32B | 4.06B | 4.09B | 5.73B | 5.79B |
| Net Income | 1.06B | 1.79B | 2.68B | 3.00B | 4.11B | 4.54B |
Balance Sheet | ||||||
| Total Assets | 51.92B | 57.30B | 30.32B | 22.54B | 19.66B | 18.30B |
| Cash, Cash Equivalents and Short-Term Investments | 4.59B | 3.26B | 2.90B | 8.21B | 4.84B | 5.26B |
| Total Debt | 2.08B | 4.00B | 2.79B | 649.96M | 703.41M | 971.27M |
| Total Liabilities | 11.96B | 16.96B | 11.91B | 2.03B | 2.31B | 3.02B |
| Stockholders Equity | 38.95B | 39.11B | 16.97B | 20.51B | 17.35B | 15.27B |
Cash Flow | ||||||
| Free Cash Flow | 1.71B | 1.35B | 1.32B | 3.07B | 1.65B | 2.55B |
| Operating Cash Flow | 2.61B | 3.55B | 2.88B | 3.58B | 4.51B | 3.30B |
| Investing Cash Flow | -1.94B | -2.58B | -2.55B | -3.62B | -1.95B | -1.36B |
| Financing Cash Flow | -828.50M | -1.49B | 33.20M | -138.02M | -2.36B | -1.56B |
Suven Pharmaceuticals Ltd. Technical Analysis
Neutral
891.10
Price Trends
444.57
Positive
440.45
Positive
424.92
Positive
Market Momentum
1.54
Positive
47.60
Neutral
21.76
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:COHANCE, the sentiment is Neutral. The current price of 891.1 is above the 20-day moving average (MA) of 453.44, above the 50-day MA of 444.57, and above the 200-day MA of 424.92, indicating a neutral trend. The MACD of 1.54 indicates Positive momentum. The RSI at 47.60 is Neutral, neither overbought nor oversold. The STOCH value of 21.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:COHANCE.
Suven Pharmaceuticals Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ₹301.97B | 60.66 | ― | 0.14% | 78.33% | 182.61% | |
64 Neutral | ₹225.41B | 33.60 | ― | 0.19% | 24.83% | 36.88% | |
60 Neutral | ₹1.06T | 97.23 | ― | 0.10% | 22.62% | 114.66% | |
56 Neutral | ₹168.34B | 104.31 | ― | 1.68% | 41.24% | -70.51% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | ₹36.01B | -1,337.77 | ― | 0.45% | 15.49% | -112.78% | |
47 Neutral | ₹163.28B | 46.10 | ― | 0.49% | 16.27% | -23.50% |
* General Sector Average
IN:COHANCE
Suven Pharmaceuticals Ltd.
440.00
-544.35
-55.30%
IN:GRANULES
Granules India Limited
909.65
377.41
70.91%
IN:JUBLPHARMA
Jubilant Pharmova Limited
1,025.10
-90.23
-8.09%
IN:LAURUSLABS
Laurus Labs Ltd.
1,970.35
1,077.98
120.80%
IN:NEULANDLAB
Neuland Laboratories Ltd.
23,536.20
7,872.60
50.26%
IN:SOLARA
Solara Active Pharma Sciences Ltd.
749.05
72.10
10.65%
Suven Pharmaceuticals Ltd. Corporate Events
Berhyanda affirms no new encumbrances on Cohance Lifesciences promoter shares for FY 2025-26
Jun 23, 2026
Berhyanda Limited, a promoter of Cohance Lifesciences Limited (formerly Suven Pharmaceuticals), has informed Indian stock exchanges that it and its persons acting in concert have not created any new encumbrances on their shares in the company duri...
Cohance Lifesciences CFO and Whole-Time Director Himanshu Agarwal to Resign in September 2026
Jun 17, 2026
Cohance Lifesciences Limited has announced that Himanshu Agarwal, its whole-time director and chief financial officer, has tendered his resignation to pursue a professional opportunity outside the organisation. He will continue in his role until t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.